Q3 EPS Estimate for Kymera Therapeutics Raised by Analyst

Key Points

• Brookline Capital Management has revised its Q3 2025 earnings estimate for Kymera Therapeutics to ($0.86) per share, up from a previous estimate of ($0.92).
• Kymera Therapeutics reported Q2 earnings on August 11, showing a loss of ($0.95) per share, which missed the consensus estimate of ($0.83), alongside a revenue of $11.48 million.
• A significant transaction occurred when CEO Nello Mainolfi sold 30,000 shares at an average price of $49.00, resulting in a 4.34% decrease in his ownership stake in the company.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Stock analysts at Brookline Capital Management upped their Q3 2025 earnings per share estimates for Kymera Therapeutics in a report issued on Monday, August 11th. Brookline Capital Management analyst L. Cann now expects that the company will earn ($0.86) per share for the quarter, up from their previous estimate of ($0.92). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($3.24) EPS, FY2026 earnings at ($4.31) EPS, FY2027 earnings at ($4.76) EPS, FY2028 earnings at ($5.69) EPS and FY2029 earnings at ($5.13) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 31.60%. The firm had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. During the same period last year, the company posted ($0.58) earnings per share. Kymera Therapeutics's revenue for the quarter was down 55.1% on a year-over-year basis.

Other equities analysts have also issued reports about the company. HC Wainwright reissued a "buy" rating and set a $60.00 price objective (up from $54.00) on shares of Kymera Therapeutics in a report on Thursday, June 26th. Wells Fargo & Company cut their price target on Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a report on Thursday, June 26th. Morgan Stanley began coverage on Kymera Therapeutics in a report on Thursday, July 3rd. They issued an "overweight" rating and a $70.00 price target for the company. Wall Street Zen lowered Kymera Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Finally, JPMorgan Chase & Co. raised their price target on Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a report on Tuesday, June 3rd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $59.11.

Kymera Therapeutics Stock Performance

NASDAQ KYMR traded down $0.6150 on Thursday, hitting $43.0050. 213,965 shares of the stock traded hands, compared to its average volume of 746,282. The business's fifty day moving average is $44.57 and its two-hundred day moving average is $36.47. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $53.27. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of -12.39 and a beta of 2.18.

Institutional Investors Weigh In On Kymera Therapeutics

A number of large investors have recently added to or reduced their stakes in KYMR. Commodore Capital LP purchased a new stake in Kymera Therapeutics during the second quarter valued at about $32,730,000. Wellington Management Group LLP raised its position in Kymera Therapeutics by 13.0% during the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock valued at $164,134,000 after purchasing an additional 689,547 shares in the last quarter. Avoro Capital Advisors LLC raised its position in Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock valued at $207,184,000 after purchasing an additional 650,000 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in Kymera Therapeutics during the fourth quarter valued at about $23,856,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock valued at $24,535,000 after purchasing an additional 491,737 shares in the last quarter.

Insider Buying and Selling

In related news, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the sale, the chief executive officer owned 660,482 shares in the company, valued at approximately $32,363,618. This trade represents a 4.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Bros. Advisors Lp Baker purchased 655,500 shares of the stock in a transaction on Monday, June 30th. The shares were purchased at an average price of $44.00 per share, for a total transaction of $28,842,000.00. Following the transaction, the director directly owned 6,117,295 shares of the company's stock, valued at approximately $269,160,980. This represents a 12.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 48,349 shares of company stock valued at $2,334,301 in the last ninety days. 16.01% of the stock is owned by insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.